<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240006</url>
  </required_header>
  <id_info>
    <org_study_id>PM024</org_study_id>
    <nct_id>NCT00240006</nct_id>
  </id_info>
  <brief_title>A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone</brief_title>
  <official_title>An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample
      of MS patients who are at high risk of nonadherence and receive support from Shared
      Solutions® and their MS Center versus those who receive support only from Shared Solutions®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence rate of Copaxone therapy by procedural intervention</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance of treatment, positive experience of treatment, levels of depression, proportion of time spent, self injection competency ratings, and the risk of non-adherence/non-compliance</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shared Solutions®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shared Solutions® and MS Center/Office Practice Partnership</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Shared Solutions® plus MS Center v. Shared Solutions®</intervention_name>
    <description>Copaxone</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, 18 years of age or older.

          2. Diagnosed with Relapsing Remitting Multiple Sclerosis (relapses accepted).

          3. Beginning or restarting therapy with Glatiramer Acetate (Copaxone®).

          4. Willing and able to complete all procedures and evaluations related to the study.

          5. Willing to provide informed consent.

        Exclusion Criteria:

          1. Taking any other immunomodulatory or immunosuppressant therapy in conjunction with
             Copaxone®.

          2. Has a significant medical illness other than MS that may interfere with the assessment
             of endpoints or the subject's participation in the trial for the full duration of the
             study.

          3. Any situation that the investigator or nurse (if not the investigator) feel may
             interfere with participation in the study.

          4. Pregnant or trying to become pregnant, or breast feeding during the study.

          5. Previously participated in this study or another clinical research study in the past
             30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MerriKay Oleen-Burkey, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mswatch.com</url>
    <description>For more information about Multiple Sclerosis</description>
  </link>
  <link>
    <url>http://www.sharedsolutions.com</url>
    <description>For more information about Shared Solutions</description>
  </link>
  <link>
    <url>http://www.tevaneuro.com</url>
    <description>For more information about Teva Neuroscience, Inc.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, Senior Director of Pan Am Clinical Operations</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Copaxone®</keyword>
  <keyword>Shared Solutions®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

